{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:40:05Z","timestamp":1790062805002,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.tiv.2015.01.014","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T18:02:53Z","timestamp":1423332173000},"page":"621-630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach"],"prefix":"10.1016","volume":"29","author":[{"given":"Caroline","family":"Bauch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Bevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Woodhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Dilworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.tiv.2015.01.014_b0005","first-page":"139","article-title":"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol","volume":"3","author":"Bendtsen","year":"1989","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.tiv.2015.01.014_b0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0891-5520(03)00066-7","article-title":"Intracellular pharmacodynamics of antibiotics","volume":"17","author":"Carryn","year":"2003","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.tiv.2015.01.014_b0015","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1177\/0192623309352496","article-title":"A strategy for risk management of drug-induced phospholipidosis","volume":"37","author":"Chatman","year":"2009","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.tiv.2015.01.014_b0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/bjc.1979.10","article-title":"Describing the validity of carcinogen screening tests","volume":"39","author":"Cooper","year":"1979","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tiv.2015.01.014_b0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.taap.2009.04.002","article-title":"Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity","volume":"237","author":"Cosgrove","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tiv.2015.01.014_b0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cbi.2009.07.019","article-title":"Cytometric analysis for drug-induced steatosis in HepG2 cells","volume":"181","author":"Donato","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tiv.2015.01.014_b0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.1994.tb04293.x","article-title":"Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine","volume":"37","author":"Firkusny","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tiv.2015.01.014_b0040","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1469-0691.2009.03074.x","article-title":"Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose","volume":"16","author":"Goncalves-Pereira","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.tiv.2015.01.014_b0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2125.1999.00973.x","article-title":"Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline","volume":"48","author":"Gupta","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tiv.2015.01.014_b0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/019262339702500111","article-title":"Cationic amphiphilic drug-induced phospholipidosis","volume":"25","author":"Halliwell","year":"1997","journal-title":"Toxicol. Pathol."},{"issue":"2010","key":"10.1016\/j.tiv.2015.01.014_b0055","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/tx9003825","article-title":"Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds","volume":"23","author":"Hanumegowda","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tiv.2015.01.014_b0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0022-3565(25)20091-X","article-title":"Gentamicin or chlorphentermine induction of phospholipidosis in the developing organism: role of tissue and species in manifestation of toxicity","volume":"232","author":"Kacew","year":"1985","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"10.1016\/j.tiv.2015.01.014_b0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/toxsci\/kfj067","article-title":"Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential","volume":"90","author":"Kasahara","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2015.01.014_b0075","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1124\/dmd.112.050054","article-title":"Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)","volume":"41","author":"Kazmi","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2015.01.014_b0080","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1165\/ajrcmb\/4.4.369","article-title":"Amiodarone- and desethylamiodarone-induced pulmonary phospholipidosis, inhibition of phospholipases in vivo, and alteration of [14C]amiodarone uptake by perfused lung","volume":"4","author":"Kodavanti","year":"1991","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.tiv.2015.01.014_b0085","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/15376510701857262","article-title":"Development of a phospholipidosis database and predictive quantitative structure\u2013activity relationship (QSAR) models","volume":"18","author":"Kruhlak","year":"2008","journal-title":"Toxicol. Mech. Meth."},{"key":"10.1016\/j.tiv.2015.01.014_b0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ab.2004.01.010","article-title":"Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99","volume":"327","author":"Lemieux","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.tiv.2015.01.014_b0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1758-2946-4-2","article-title":"Predicting the mechanism of phospholipidosis","volume":"4","author":"Lowe","year":"2012","journal-title":"J. Cheminform."},{"key":"10.1016\/j.tiv.2015.01.014_b0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10565-006-0176-z","article-title":"Validation of an in vitro screen for phospholipidosis using a high-content biology platform","volume":"22","author":"Morelli","year":"2006","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.tiv.2015.01.014_b0105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/ki.1980.176","article-title":"Gentamicin-induced nephrotoxicity: a cell biology approach","volume":"18","author":"Morin","year":"1980","journal-title":"Kidney Int."},{"key":"10.1016\/j.tiv.2015.01.014_b0110","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/cmdc.201200306","article-title":"Identification of drugs inducing phospholipidosis by novel in vitro data","volume":"7","author":"Muehlbacher","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.tiv.2015.01.014_b0115","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tiv.2010.12.010","article-title":"A high content screening assay for identifying lysosomotropic compounds","volume":"25","author":"Nadanaciva","year":"2011","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.tiv.2015.01.014_b0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/toxsci\/kfm157","article-title":"In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies","volume":"99","author":"Nioi","year":"2007","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2015.01.014_b0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1293\/tox.21.9","article-title":"Drug-induced phospholipidosis-pathological aspects and its prediction","volume":"21","author":"Nonoyama","year":"2008","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.tiv.2015.01.014_b0130","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00204-006-0091-3","article-title":"High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening","volume":"80","author":"O\u2019Brien","year":"2006","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tiv.2015.01.014_b0135","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/minf.201200048","article-title":"Construction and consensus performance of (Q)SAR models for predicting phospholipidosis using a dataset of 743 compounds","volume":"31","author":"Orogo","year":"2012","journal-title":"Mol. Inform."},{"key":"10.1016\/j.tiv.2015.01.014_b0140","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0006-2952(85)90183-2","article-title":"Inhibition of purified lysosomal phospholipase A1 by beta-adrenoceptor blockers","volume":"34","author":"Pappu","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tiv.2015.01.014_b0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2131\/jts.37.261","article-title":"In vitro validation of drug-induced phospholipidosis","volume":"37","author":"Park","year":"2012","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.tiv.2015.01.014_b0150","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/ci6004542","article-title":"Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential","volume":"47","author":"Pelletier","year":"2007","journal-title":"J. Chem. Inform. Model."},{"key":"10.1016\/j.tiv.2015.01.014_b0155","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.vascn.2013.08.001","article-title":"A high content screening assay to predict human drug-induced liver injury during drug discovery","volume":"68","author":"Persson","year":"2013","journal-title":"J. Pharmacol. Toxicol. Meth."},{"key":"10.1016\/j.tiv.2015.01.014_b0160","first-page":"347","article-title":"Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines","volume":"55","author":"Ploemen","year":"2004","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.tiv.2015.01.014_b0170","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/153537020122600903","article-title":"Drug-induced phospholipidosis: are there functional consequences?","volume":"226","author":"Reasor","year":"2001","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.tiv.2015.01.014_b0165","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14740338.5.4.567","article-title":"Drug-induced phospholipidosis: issues and future directions","volume":"5","author":"Reasor","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.tiv.2015.01.014_b0175","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0090-9556(24)15237-3","article-title":"Flavin-containing monooxygenase-mediated metabolism of N-deacetyl ketoconazole by rat hepatic microsomes","volume":"27","author":"Rodriguez","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tiv.2015.01.014_b0180","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/toxsci\/kfh264","article-title":"A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system","volume":"83","author":"Sawada","year":"2005","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2015.01.014_b0185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tiv.2015.01.014_b0190","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/(SICI)1520-636X(1996)8:6<411::AID-CHIR1>3.0.CO;2-F","article-title":"Toxic doses of rac-, (\u2212)-(S)- and (+)-(R)-propranolol in rats and rabbits","volume":"8","author":"Toet","year":"1996","journal-title":"Chirality"},{"key":"10.1016\/j.tiv.2015.01.014_b0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/toxsci\/kfs083","article-title":"Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs","volume":"127","author":"Tolosa","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2015.01.014_b0200","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2131\/jts.31.315","article-title":"Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential","volume":"31","author":"Tomizawa","year":"2006","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.tiv.2015.01.014_b0205","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0006-2952(78)90370-2","article-title":"The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts","volume":"27","author":"Tulkens","year":"1978","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tiv.2015.01.014_b0215","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.tiv.2011.05.026","article-title":"High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis","volume":"25","author":"van de Water","year":"2011","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.tiv.2015.01.014_b0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1289\/ehp.6643","article-title":"Interlaboratory evaluation of rat hepatic gene expression changes induced by methapyrilene","volume":"112","author":"Waring","year":"2004","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.tiv.2015.01.014_b0225","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0300-483X(94)90030-2","article-title":"Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole","volume":"94","author":"Whitehouse","year":"1994","journal-title":"Toxicology"},{"key":"10.1016\/j.tiv.2015.01.014_b0230","unstructured":"Willard, J., 2008. FDA Phospholipidosis Working Group, preliminary results and developing opinions\u201d presented at the Society of Toxicology (STP) continuing education course on drug-induced phospholipidosis. In: Society of Toxicology Pathology 27th Annual Symposium, San Francisco, CA."},{"key":"10.1016\/j.tiv.2015.01.014_b0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/toxsci\/kfn109","article-title":"Cellular imaging predictions of clinical drug-induced liver injury","volume":"105","author":"Xu","year":"2008","journal-title":"Toxicol. Sci."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233315000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233315000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T13:46:04Z","timestamp":1747575964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233315000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0887233315000156"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2015.01.014","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2015.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}